Akademik Veri Yönetim Sistemi
SKINmed, cilt.18, sa.2, ss.84-90, 2020 (Scopus)
© 2020, Pulse Marketing and Communications LLC. All rights reserved.The introduction of biologic therapy has resulted in a major change in treatment eff icacies, especially in conventional treatment-resistant psoriasis patients. This study is to assess the eff icacy of biologic agents in conventional treatment-resistant patients regarding Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) after therapy. Patients were monitored prospec-tively for 24 weeks after the initiation of etanercept, adalimumab, or ustekinumab therapy. PASI 75/90/100 responses and the number of patients with 0/1 DLQI score were compared. In the patients who used etanercept, adalimumab, and ustekinumab therapies, PASI 75 responses were found as 61.5%, 57.9%, and 84.6%, respectively, in the 12th week, while they were found as 72.7%, 76.9%, and 90.9% in the 24th week, and no statistically signif icant difference was found between the three groups (P > 0.05). The percentage of patients who had a DLQI score of 0 and 1 were 30.8%, 42.1%, and 38.5% in the 12th week (P = 0.92) and 36.4%, 61.5%, and 45.5% in the 24th week (P > 0.45) for etanercept, adalimumab, and ustekinumab therapies, respectively. As a result, no signif icant differences were found between biologic agents concerning improvement in both clinical response (PASI and VYA) and quality of life (DLQI and PDI).